Business Context and Reporting Period
Company: Indaptus Therapeutics, Inc. (INDP)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Indaptus is a clinical-stage biotechnology company developing Decoy20, a systemically-administered anti-cancer and anti-viral immunotherapy based on attenuated, non-pathogenic Gram-negative bacteria. The company has discontinued enrollment in its Phase 1 Combination Study (Decoy20 with Tislelizumab) and currently has no plans to initiate new clinical trials. The company is actively evaluating strategic options for a "Post-Investment Transaction," including the acquisition of a target company.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(20.85) million | $(15.02) million |
| Operating Expenses | $19.83 million | $15.37 million |
| Cash and Cash Equivalents (Dec 31, 2025) | $8.51 million | $5.79 million |
| Accumulated Deficit (Dec 31, 2025) | $(81.29) million | $(60.44) million |
| Net Cash Used in Operating Activities | $(14.82) million | $(12.32) million |
| Net Cash Provided by Financing Activities | $17.54 million | $4.75 million |
Note: The company has no revenue and is not profitable. The 2025 net loss includes a $1.15 million non-cash charge for the change in fair value of convertible promissory notes.
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss increased by 38.8% to $20.85 million, driven by a 29.1% increase in total operating expenses.
- R&D Expenses: Increased by $2.09 million (28.8%) primarily due to higher clinical trial costs ($1.5 million) and payroll expenses ($0.6 million) related to executive modification agreements.
- G&A Expenses: Increased by $2.38 million (29.3%) due to higher payroll ($1.9 million) and transaction-related expenses ($1.4 million) associated with the June 2025 financing, partially offset by lower D&O insurance costs.
- Capital Structure: Significant changes occurred via a 1-for-28 reverse stock split in June 2025 and a December 2025 investment transaction with David E. Lazar.
Guidance, Outlook, Risks, and Unusual Items
Recent Developments and Strategic Shift
Lazar Investment Transaction: On December 22, 2025, the company raised $6.0 million by issuing 1,000,000 shares of Series AA and Series AAA Preferred Stock to David E. Lazar. These shares are convertible into 111,000,000 shares of common stock. Upon conversion, Mr. Lazar will beneficially own approximately 96.4% of the company on a fully diluted basis. The company plans to pursue a strategic transaction (acquisition or investment) using these proceeds.
Warrant Repricing: In February 2026, the company repriced warrants to purchase approximately 1.68 million shares, reducing the exercise price to $1.75 per share to comply with Nasdaq minimum price rules.
Clinical Status: Enrollment in the Decoy20 Combination Study has been discontinued. There are no participants remaining, and no new trials are planned.
Liquidity and Going Concern
The company has identified conditions raising substantial doubt about its ability to continue as a going concern. As of December 31, 2025, cash balances of $8.51 million are projected to fund operations only into the second quarter of 2026. The company will require additional equity or debt financing to continue operations or consummate a strategic transaction.
Key Risks
- Dilution: Conversion of the Lazar Preferred Stock will result in significant dilution to existing shareholders and a change in control.
- Capital Needs: Failure to secure additional financing may force the company to delay, limit, or eliminate research programs or cease operations.
- Strategic Transaction Uncertainty: There is no assurance the company will identify or successfully close a Post-Investment Transaction.
- Regulatory Compliance: The company faces risks related to Nasdaq listing standards, including minimum market value of listed securities (MVLS) and minimum bid price requirements.
Investor Verification Checklist
- Going Concern Status: Verify the company's ability to secure financing beyond Q2 2026 to avoid insolvency.
- Preferred Stock Conversion: Confirm the timeline and conditions for the conversion of Lazar's 1,000,000 preferred shares into 111 million common shares.
- Strategic Transaction Progress: Monitor updates on the search for a "Target Company" for acquisition or investment.
- Warrant Exercise Prices: Note the recent reduction of warrant exercise prices to $1.75 and the potential for future dilution upon exercise.
- Clinical Pipeline: Acknowledge that the company has no active clinical trials and no approved products generating revenue.